The NETest: The Clinical Utility of Multigene Blood Analysis in the Diagnosis and Management of Neuroendocrine Tumors. - PubMed - NCBI

The NETest: The Clinical Utility of Multigene Blood Analysis in the Diagnosis and Management of Neuroendocrine Tumors. - PubMed - NCBI

Endocrinol Metab Clin North Am. 2018 Sep;47(3):485-504. doi: 10.1016/j.ecl.2018.05.002.

The NETest: The Clinical Utility of Multigene Blood Analysis in the Diagnosis and Management of Neuroendocrine Tumors.

Modlin IM1, Kidd M2, Malczewska A3, Drozdov I2, Bodei L4, Matar S2, Chung KM2.

Author information

Abstract

The neuroendocrine neoplasms test (NETest) is a multianalyte liquid biopsy that measures neuroendocrine tumor gene expression in blood. This unique signature precisely defines the biological activity of an individual tumor in real time. The assay meets the 3 critical requirements of an optimal biomarker: diagnostic accuracy, prognostic value, and predictive therapeutic assessment. NETest performance metrics are sensitivity and specificity and in head-to-head comparison are 4-fold to 10-fold more accurate than chromogranin A. NETest accurately identifies completeness of surgery and response to somatostatin analogs. Clinical registry data demonstrate significant clinical utility in watch/wait programs.

KEYWORDS:

Biomarker; Blood; Bronchopulomary carcinoid; Multigene blood analysis; NETest; Neuroendocrine tumors; PCR; Peptide receptor radionuclide therapy; Progression; Transcript

PMID:

 

30098712

 

DOI:

 

10.1016/j.ecl.2018.05.002